Sinan Zhu, Ph.D.
Affiliations: | 2013 | Molecular Medicine and Translational Science | Wake Forest University, Winston-Salem, NC, United States |
Area:
OncologyGoogle:
"Sinan Zhu"Parents
Sign in to add mentorGuangchao Sui | grad student | 2013 | Wake Forest | |
(The role of Dmp1 in human breast cancer prognosis and cyclin D1-induced breast cancer.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Hassan MS, Pullikuth A, Nelson KC, et al. (2020) Beta2-adrenoreceptor signaling increases therapy-resistance in prostate cancer by upregulating MCL1. Molecular Cancer Research : McR |
Ran L, Sirota I, Cao Z, et al. (2015) Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discovery. 5: 304-15 |
Lee W, Teckie S, Wiesner T, et al. (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics. 46: 1227-32 |
Fry EA, Taneja P, Maglic D, et al. (2013) Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. Plos One. 8: e77870 |
Zhu S, Mott RT, Fry EA, et al. (2013) Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer. The American Journal of Pathology. 183: 1339-50 |
Maglic D, Zhu S, Fry EA, et al. (2013) Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 32: 4120-9 |
Maglic D, Kendig R, Fry E, et al. (2012) Abstract 4158: MEKK1 regulates DMP1 transcriptional activity via phosphorylation and predicts breast cancer patient outcome Cancer Research. 72: 4158-4158 |
zhu s. (2012) Abstract 2052: Regulation of p16Ink4a - Rb pathway by Cyclin D1- Dmp1 interaction Cancer Research. 72: 2052-2052 |
Zhu S, Taneja P, Kendig R, et al. (2011) Abstract 2958: Cyclin D1 regulates the ARF and INK4a promoters Cancer Research. 71: 2958-2958 |
Taneja P, Maglic D, Kai F, et al. (2010) Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights. Oncology. 4: 15-34 |